Xolremdi Generic: When Will Generic Mavorixafor Be Available?
This page is aggregated from FDA records, court filings and company announcements. Coded and designed by Dr. Brian Staiger, PharmD, BCPS
Updated October 9, 2026 How we build our data
Xolremdi Generic at a Glance
Four quick answers from FDA records and our estimate.
- When is the first generic expected? April 2038 About 11.5 years away Why then?
- Has the FDA approved a generic? Not yet None in the FDA’s records yet Why not yet?
- When does the last patent end? December 2038 6 patents listed with the FDA Why is a generic expected sooner?
- Can you buy a generic today? Not yet No company lists one for sale
Generic mavorixafor is expected to be available in April 2038, about 11.5 years away. None is for sale yet.
Why April 2038?
It is when Xolremdi’s patent 10,610,527 ends. That patent covers a way of using it, and once it ends, generics should be able to go on sale as soon as the FDA approves them. It is too early to rate how firm that is.
If Xolremdi’s last patent runs to December 2038, how can a generic come sooner?
The 3 patents that run past the expected month, to December 2038 (10,548,889, 11,045,461 and 12,115,156), cover the product’s formulation. A patent like that protects one way of making or using the medicine, not the medicine itself. A generic company can often make its version a different way or leave that use off its label, or a court can rule the patent invalid or not infringed. That is why the expected month comes before the last protection ends. See the road to a generic
Why hasn’t the FDA approved a generic yet?
That is normal before a launch. The FDA usually can’t give a generic its final approval while a patent or exclusivity still blocks it, so final approval often comes close to the day the generic can be sold. No company holds a “tentative” approval yet either (the FDA’s word for a generic that is ready but still blocked).
Will the generic cost less?
Usually, but no company is recorded as having applied to make one yet, and a single company usually brings only a modest drop. See the price pattern
What should I do now?
Keep taking Xolremdi as prescribed. When a generic arrives, your pharmacy may switch you to it automatically, and it may look different. What a generic means for you
Our month is only an estimate based on available information, so we never name a day.
Xolremdi by the Numbers
- Reason
- Patent expiresA patent that protects the brand runs out. After that, approved generics can be sold.
- How sure
- Not rated Too early to rate. The month is where the records point today.
- Price competition
- None filed yet No filers on record
- Brand sales
- $7M a yearSmaller seller
- FDA approved 2024 April 2024 FDA Orange Book
- Patents listed 6 last runs to December 2038 A generic is expected sooner, in April 2038. See why FDA Orange Book
- Medicare Part D spent $635.8K in 2025 CMS Part D Spending by Drug
Xolremdi’s Road to a Generic
Xolremdi has had the market to itself since the FDA approved it in April 2024 (X4 Pharmaceuticals Inc). Its FDA protection (orphan drug) runs to April 2031. Its 6 listed patents run to December 2038.
The first generic of Xolremdi is expected in April 2038.
Why that month: patent 10,610,527, on a way of using it, ends then. That is a few months before the last listed patent runs out, in December 2038.
Why a Generic Can Come Before December 2038
The last listed patent runs to December 2038, but it covers the product’s formulation, not the medicine itself, which a generic can often work around or challenge. Dr. Brian explains
Each bar runs from the brand’s approval to the day that protection ends. The green band is our projection for the first generic: a month, never a day, because legal dates move and a generic reaches shelves days to weeks after it is allowed. Sources: FDA Orange Book; the expected month from court records and company announcements.
Xolremdi Patents and FDA Protections
Every patent and exclusivity the FDA Orange Book lists for Xolremdi’s own applications. A protection running past the expected month does not mean the date is wrong: a settlement or a court ruling can let a generic in before a patent ends, and a patent on one formulation or use does not block every generic.
The one that matters for a generic launch: patent 10,610,527, which ends in December 2036; the first generic is expected after it, in April 2038, about 11.5 years away. Why the later ones may not hold it back
| Patent | What it covers | Protects until | Status |
|---|---|---|---|
| 10,953,003 | The product’s formulation | December 2036 | Active |
| 10,610,527 Sets the expected month of generic availability | A way of using it (U-3932) | December 2036 | Active |
| 11,219,621 | A way of using it (U-3932) | December 2036 | Active |
| 10,548,889 | The product’s formulation | December 2038 | Active |
| 11,045,461 | The product’s formulation | December 2038 | Active |
| 12,115,156 | The product’s formulation | December 2038 | Active |
| Exclusivity | What it means | Ends | Status |
|---|---|---|---|
| New chemical entity NCE | Five years of protection for a medicine whose active ingredient the FDA had never approved before. | April 2029 | Active |
| Orphan drug ODE-480 | Seven years of protection for a use in a rare disease. | April 2031 | Active |
Source: FDA Orange Book, application 218709. Patent numbers open the patent on Google Patents.
Who Is Lined Up to Make Generic Mavorixafor
Three steps stand between a brand and a generic you can buy: a company applies to the FDA, the FDA approves it, and the company starts selling it.
Applied to the FDA
No company is recorded as having applied to the FDA to make a generic Xolremdi yet.
Approved by the FDA
Not yet. The FDA has not approved a generic mavorixafor. Final approval often comes close to the day a generic can be sold.
For Sale in Pharmacies
Not yet. No company lists a generic mavorixafor for sale with the FDA.
Sources: how many companies have applied, from court records and company announcements; approved generics from the FDA Orange Book; tentative approvals from Drugs@FDA; what is for sale from the FDA NDC Directory. The FDA does not disclose an application before it approves it (21 CFR 314.430).
Xolremdi Price: What Pharmacies Pay and What Generics Usually Do
What a Generic Could Cost
How we estimate it. The national survey of what pharmacies pay (NADAC) has no recent price for Xolremdi, so we cannot show dollars. Here is the FDA’s finding of how far the price pharmacies pay usually falls as generic companies join: about 31% with one company, 44% with two, 73% with four and over 95% with six or more (the typical drop for every drug whose first generic came out from 2015 to 2017).
Median prices pharmacies paid for the generic (invoice prices), compared with the brand’s price before generic entry, from FDA’s 2019 analysis “Generic Competition and Drug Prices”. At the manufacturer’s price FDA found steeper drops (about 39%, 54%, 79% and over 95%), the figures quoted elsewhere on this tracker. A typical pattern, not a price quote for this medicine.
What Medicare and Medicaid Spend on Xolremdi
Big public spending is part of why generic makers line up for a medicine, and why its first generic matters beyond the pharmacy counter. Figures are before manufacturer rebates, which are confidential.
Medicare Part D Spending
What Medicare drug plans spent on Xolremdi, before manufacturer rebates.
- $635.8K
- 2025, the whole year
About $42,388 per prescription fill
See the numbers
| Period | Spending | People | Per fill |
|---|---|---|---|
| 2025 | $635,827 | – | $42,388.49 |
Source: CMS Medicare Part D Spending by Drug, matched by the brand name Xolremdi only, so no generic is counted in it. What CMS says it is used for: Drug uses not available.
Xolremdi Strengths and Forms
| Strength | Form | How it is taken | Approved | Status |
|---|---|---|---|---|
| 100MG | Capsule | Oral | April 2024 | Prescription reference product |
Source: FDA Orange Book, X4 Pharmaceuticals Inc. Listed for sale today by X4 Pharmaceuticals, Inc. (FDA NDC Directory).
Xolremdi NDC Codes and Packages
Each Xolremdi package sold today has its own NDC, the product number printed on the box and on the pharmacy label. Open one to see that package’s details, what pharmacies pay for it and its patent timeline.
| NDC | Product | Package | Company |
|---|---|---|---|
| 83296-0100-12 | MAVORIXAFOR 100 mg/1 capsule, gelatin coated | bottle of 120 capsules | X4 Pharmaceuticals, Inc. |
| 83296-0100-60 | MAVORIXAFOR 100 mg/1 capsule, gelatin coated | bottle of 60 capsules | X4 Pharmaceuticals, Inc. |
| 83296-0100-90 | MAVORIXAFOR 100 mg/1 capsule, gelatin coated | bottle of 90 capsules | X4 Pharmaceuticals, Inc. |
Source: the FDA NDC Directory, current listings only. Only packages sold under Xolremdi’s own FDA approval (NDA 218709) are listed, never a generic. Some codes belong to companies that repackage Xolremdi: it is the same medicine in a different package.
What a Generic Xolremdi Means for You
Nothing Changes Until It Is in Pharmacies
Until a generic is actually for sale, keep filling Xolremdi as usual. When one arrives, there is nothing you need to sign up for.
Your Pharmacy May Switch You Automatically
Every state lets pharmacists fill a brand-name prescription with an FDA-approved generic rated as equivalent to it, and about 19 states require them to, unless your prescriber writes “dispense as written” or “brand medically necessary” on the prescription. Some states ask the pharmacist to tell you, or to get your OK first. A study of every state’s law has the details.
It Will Probably Look Different
US trademark law does not let a generic look exactly like the brand, so the color, shape or markings usually change. The active ingredient, strength and form are the same. An “authorized generic,” made by or for the brand’s own company, can look identical. The FDA explains.
Your Insurance May Change Too
Once a lower-cost version is available, many insurance plans charge more for the brand, or stop covering it. Your plan’s drug list (formulary) says how.
Until a generic is on US pharmacy shelves, be careful with websites that offer “generic Xolremdi”. The FDA warns that unlicensed online pharmacies sell counterfeit and unapproved medicines; its BeSafeRx page shows how to check a pharmacy.
Questions people ask about Xolremdi
Is there a generic for Xolremdi right now?
No. As of October 9, 2026 no generic mavorixafor is listed for sale in the FDA NDC Directory.
When will Xolremdi go generic?
April 2038 is the expected month. It is when Xolremdi’s patent 10,610,527 ends. That patent covers a way of using it, and once it ends, generics should be able to go on sale as soon as the FDA approves them. The last listed patent runs to December 2038, but it covers the product’s formulation, not the medicine itself, which a generic can often work around or challenge.
Will generic mavorixafor be the same as Xolremdi?
Yes in the ways that matter: the same active ingredient, strength and form, with proof that it reaches your blood the same way. Inactive ingredients can differ, which is why some people notice a different look or taste.
How much will the generic cost?
Nobody can say for sure before launch. No company is recorded as having applied to the FDA to make one yet, and a single company usually brings only a modest drop.
Has the FDA approved a generic Xolremdi?
Not yet. The FDA Orange Book lists no approved generic version of Xolremdi.
When does the Xolremdi patent expire?
The FDA Orange Book lists 6 patents for Xolremdi; the last runs to December 2038. The one behind the expected month is patent 10,610,527, which ends in December 2036. A patent date is not the launch date: settlements and court rulings often bring a generic earlier, and FDA approval or a company’s own plans can make it later. The expected month on this page (April 2038) weighs all of that.
Changes to This Projection
- First generic expected April 2038 on this month’s schedule. A line is added here whenever a monthly update moves the month, the reason or how sure it is.
Every change to the expected month is logged here with the month we saw it.
Also Going Generic
- Venlafaxine BesylateVenlafaxine BesylateMay 2028
- NithiodoteSodium Thiosulfate and Sodium NitriteDecember 2031
- RuzurgiAmifampridineJune 2032
- AgamreeVamoroloneApril 2034
- InluriyoImlunestrantSeptember 2039
- DetectnetCopper Cu-64 DotatateSeptember 2041
About Xolremdi
- Generic name mavorixafor
- How it is taken By mouth
- Company X4 Pharmaceuticals Inc
- More drugs Brand-name drugs starting with X
- Have a question? A pharmacist answers, free. Ask about Xolremdi
Sources. The expected month: FDA Paragraph IV Patent Certifications list, federal court records, company announcements and securities filings (settlement dates, launch plans, sales). The record on this page: FDA Orange Book, Drugs@FDA (tentative approvals), FDA NDC Directory, CMS Medicare Part D Spending by Drug, FDA, Generic Competition and Drug Prices (2019). Updated October 9, 2026. Information, not medical advice.